4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc is trading at $11.90, down 6.89% on the session. The 50 day average sits at $13.72 and the 200 day at $10.87, which puts the stock in a uptrend. RSI is at 44.1, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $10.62 with resistance near $13.45, so that band frames the current range. Average daily movement is roughly $0.97, or about 8.1% of the share price, which is what any stop placement has to allow for. The overall health score of 45 out of 100 combines a trend score of 61, momentum of 45 and a risk score of 18.

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.